Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio SD, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441–8.
Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, et al. Enets Consensus guidelines for the standards of Care in Neuroendocrine tumors: somatostatin receptor imaging with 111In-pentetreotide. Neuroendocrinology. 2009;90:184–9.
Article CAS PubMed Google Scholar
Kim SJ, Kim JW, Han SW, Oh DY, Lee SH, Kim DW, et al. Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. BMC Cancer. 2010;10:448.
Article PubMed PubMed Central Google Scholar
Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs, 10. International Agency for Research on Cancer. pp. 210–4; 2017.
Kubota K, Okasaki M, Minamimoto R, Miyata Y, Morooka M, Nakajima K, et al. Lesion-based analysis of (18)F-FDG uptake and (111)In-pentetreotide uptake by neuroendocrine tumors. Ann Nucl Med. 2014;28:1004–10.
Article CAS PubMed PubMed Central Google Scholar
Bodei L, Sundin A, Kidd M, Prasad V, Modlin IM. The status of neuroendocrine tumor imaging: from darkness to light? Neuroendocrinology. 2015;101:1–17.
Article CAS PubMed Google Scholar
Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.
Article CAS PubMed Google Scholar
Perri M, Erba P, Volterrani D, Lazzeri E, Boni G, Grosso M, et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging. 2008;52:323–33.
Balon HR, Brown TL, Goldsmith SJ, Silberstein EB, Krenning EP, Lang O, et al. The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J Nucl Med Technol. 2011;39:317–24.
Mizuide M, Ryozawa S, Fujita A, Ogawa T, Katsuda H, Suzuki M, et al. Complications of endoscopic ultrasound-guided fine needle aspiration: a narrative review. Diagnostics (Basel). 2020;10:964.
Singh S, Halperin DM, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: primary analysis of the phase 3 randomized NETTER-2 study. Lancet. 2024;10446:2807–17.
Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M. Neuroendocrine tumor heterogeneity adds uncertainty to the World Health Organization 2010 classification: real-World Data from the Spanish Tumor Registry (R‐GETNE). Oncologist. 2018;4:422–32.
Ito T, Masui T, Komoto I, Doi R, Osamura R, Sakurai A, et al. Clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN). Japanese Neuroendocrine Tumor Society; 2019.
Briganti V, Matteini M, Ferri P, Vaggelli L, Castagnoli A, Pieroni C. Octreoscan SPET evaluation in the diagnosis of pancreas neuroendocrine tumors. Cancer Biother Radiopharm. 2001;16:515–24.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8.
Mizutani G, Nakanishi Y, Watanabe N, Honma T, Obana Y, Seki T, et al. Expression of somatostatin receptor (SSTR) subtypes (SSTR-1, 2A, 3, 4 and 5) in neuroendocrine tumors using real-time RT-PCR method and immunohistochemistry. Acta Histochem Cytochem. 2012;45:167–76.
Article CAS PubMed PubMed Central Google Scholar
Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–98.
Comments (0)